$49.53
0.51% yesterday
Nasdaq, May 20, 10:13 pm CET
ISIN
US09073M1045
Symbol
TECH
Sector
Industry

Bio-Techne Corporation Stock price

$49.53
+2.02 4.25% 1M
-19.19 27.92% 6M
-22.50 31.24% YTD
-32.97 39.96% 1Y
-42.06 45.92% 3Y
-17.91 26.56% 5Y
+23.84 92.82% 10Y
Nasdaq, Closing price Tue, May 20 2025
+0.25 0.51%
ISIN
US09073M1045
Symbol
TECH
Sector
Industry

Key metrics

Market capitalization $7.76b
Enterprise Value $8.05b
P/E (TTM) P/E ratio 60.37
EV/FCF (TTM) EV/FCF 36.45
EV/Sales (TTM) EV/Sales 6.66
P/S ratio (TTM) P/S ratio 6.42
P/B ratio (TTM) P/B ratio 3.85
Dividend yield 0.65%
Last dividend (FY25) $0.32
Revenue growth (TTM) Revenue growth 4.72%
Revenue (TTM) Revenue $1.21b
EBIT (operating result TTM) EBIT $270.75m
Free Cash Flow (TTM) Free Cash Flow $220.76m
Cash position $140.67m
EPS (TTM) EPS $0.82
P/E forward 56.80
P/S forward 6.38
EV/Sales forward 6.61
Short interest 4.70%
Show more

Is Bio-Techne Corporation a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,789 stocks worldwide.

Bio-Techne Corporation Stock Analysis

Unlock Scores for Free

Analyst Opinions

17 Analysts have issued a Bio-Techne Corporation forecast:

11x Buy
65%
6x Hold
35%

Analyst Opinions

17 Analysts have issued a Bio-Techne Corporation forecast:

Buy
65%
Hold
35%

Financial data from Bio-Techne Corporation

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
1,209 1,209
5% 5%
100%
- Direct Costs 405 405
6% 6%
33%
804 804
4% 4%
67%
- Selling and Administrative Expenses 325 325
4% 4%
27%
- Research and Development Expense 97 97
1% 1%
8%
382 382
5% 5%
32%
- Depreciation and Amortization 111 111
0% 0%
9%
EBIT (Operating Income) EBIT 271 271
7% 7%
22%
Net Profit 132 132
35% 35%
11%

In millions USD.

Don't miss a Thing! We will send you all news about Bio-Techne Corporation directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Bio-Techne Corporation Stock News

Neutral
PRNewsWire
7 days ago
ST. PAUL, Minn. , May 14, 2025 /PRNewswire/ -- ScaleReady, in collaboration with Wilson Wolf Manufacturing, Bio-Techne Corporation (NASDAQ: TECH) and CellReady announced today three G-Rex Grants that have been awarded to faculty members at the University of Southern California (USC) and the Children's Hospital of Los Angeles (CHLA).
Neutral
PRNewsWire
9 days ago
MINNEAPOLIS , May 12, 2025 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced it will showcase its latest spatial biology and cell and gene therapy workflow solutions at the American Society of Gene & Cell Therapy (ASGCT) 2025 meeting taking place in New Orleans between May 13 th – 17th at the New Orleans Ernest N. Morial Convention Center.
Neutral
PRNewsWire
13 days ago
Kytopen and Bio-Techne announce partnership on an integrated cellular engineering workflow to expedite cell therapy manufacturing. The TcBuster™ system offers a fast and scalable method to integrate large, multigene cargos with high editing efficiency in a single vector, while Flowfect® continuous flow technology enables the gentle, high-efficiency processing of billions of cells in minutes.
More Bio-Techne Corporation News

Company Profile

Bio-Techne Corp. engages in the development, manufacture and sale of biotechnology reagents and instruments for the research and clinical diagnostic markets. It operates through the following segments: Biotechnology, Protein Platforms, Diagnostics, and Corporate. The Biotechnology segment supplies specialized proteins, such as cytokines and growth factors, immunoassays, antibodies and related reagents, as well as in situ hybridization, media and other cell culture products and reagents to the biotechnology research community. The Protein Platforms segment develops, manufactures, and sells tools to simplify protein analysis. The Diagnostics segment includes blood chemistry and blood gas quality controls, hematology instrument controls, diagnostic immunoassays, and other bulk and custom reagents for the in vitro diagnostic market worldwide. The company was founded on 1976 and is headquartered in Minneapolis, MN.

Head office United States
CEO Kim Kelderman
Employees 3,100
Founded 1976
Website www.bio-techne.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today